31 search results for: coexisting diseases

Infographic

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

5 min

Dermatology

An infographic exploring the process of allergen sensitization and the impact it may have on the development of atopic comorbidities in children with AD.

expert video

Exploring The Concept of Disease Modification in Atopic Dermatitis

13 min

Dermatology

Exploring the concept of disease modification and related pathomechanisms in atopic dermatitis.

expert video

Can Early Intervention Shape the Course of Atopic Dermatitis?

15 min

Dermatology

Exploring the concept of disease modification through early intervention with targeted systemic therapies in atopic dermatitis.

expert video

IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

53 min

Dermatology

Highlights from the WCD 2023 ADVENT symposium, exploring the distinctions and shared elements of atopic dermatitis and prurigo nodularis.

Infographic

The Role of Type 2 Inflammation in Multiple Disease Trajectories

5 min

Dermatology

How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.

Podcast

ADVENT On Air | Clinical Perspective on Pediatric Patients With Atopic Dermatitis

15 min

Dermatology

Listen to the expert perspectives of Drs. Lisa Swanson and Weily Soong on clinical considerations in pediatric patients with atopic dermatitis.

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

expert video

Can advanced systemic therapies modify pathomechanisms in AD?

5 min

Dermatology

Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.

expert video

Can early intervention modify the course of AD?

5 min

Dermatology

Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.

expert video

The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers

1 min

Dermatology

Discover the multidimensional impact of pediatric atopic dermatitis on children and caregivers – a soundbite from the Expert Lounge Canada 2022.

expert video

Children and EoE: More Than Just Being a Picky Eater

9 min

Gastroenterology

Join Prof. Alexandra Papadopoulou as she reviews the multifaceted burden of children with EoE.

videoanimation

EoE Burden and Pathophysiology of Type 2 Inflammation

3 min

Gastroenterology

Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Czech RepublicChange country/region